Phase I/II Clinical Trial in Japan for Thoracic Malignant Solid Tumors has started
Stella Pharma announces that it has started the first patient trial for the do……
Stella Pharma announces that it has started the first patient trial for the do……
At the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO),……
We are proud to announce that we will exhibit at the Osaka Healthcare Pavilion ……
We are pleased to announce that we have successfully completed the first shipme……
Stella Pharma Corporation has concluded a Memorandum of Understanding (MOU) to ……
We are pleased to announce the completion of the 90-day observation period for ……
The paper titled “Poly(vinyl alcohol) potentiating an inert D-amino acid-based ……
The Paper titled “Increased cell killing effect in neutron capture enhanced pro……
STELLA PHARMA CORPORATION announced today that our Company has entered into a D……
Our product Borofalan (10B) (development code: SPM-011), which we are developin……
Stella Pharma completed the enrollment of patients for the domestic phase II do……
Stella Pharma announces that it has signed an agreement with the National Cance……